378 related articles for article (PubMed ID: 28295447)
1. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Der-Nigoghossian C; Lesch C; Berger K
Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
[TBL] [Abstract][Full Text] [Related]
2. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
Murphy T; Dhar R; Diringer M
Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
Marik PE; Rivera R
Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
[TBL] [Abstract][Full Text] [Related]
4. Conivaptan for hyponatremia in the neurocritical care unit.
Wright WL; Asbury WH; Gilmore JL; Samuels OB
Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Annane D; Decaux G; Smith N;
Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
7. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
[TBL] [Abstract][Full Text] [Related]
9. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
10. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
[TBL] [Abstract][Full Text] [Related]
11. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
[TBL] [Abstract][Full Text] [Related]
12. Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.
Naidech AM; Paparello J; Liebling SM; Bassin SL; Levasseur K; Alberts MJ; Bernstein RA; Muro K
Neurocrit Care; 2010 Aug; 13(1):57-61. PubMed ID: 20568023
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
[TBL] [Abstract][Full Text] [Related]
14. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
[TBL] [Abstract][Full Text] [Related]
15. Intravenous conivaptan.
Moen MD; Keating GM
Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
[TBL] [Abstract][Full Text] [Related]
16. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
[TBL] [Abstract][Full Text] [Related]
17. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF; Rock AD; Woodward EJ
Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations.
Jahangiri A; Wagner J; Tran MT; Miller LM; Tom MW; Kunwar S; Blevins L; Aghi MK
J Neurosurg; 2013 Dec; 119(6):1478-83. PubMed ID: 23971964
[TBL] [Abstract][Full Text] [Related]
20. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
